Blog · Access logistics

Prior-Auth Playbook: CGM, Pump & Supply Denials

Educational · Community logistics · Sep 2026

Public diabetes forums keep returning to the same access spiral: a continuous glucose monitor (CGM) denial, a pump or supply hold, a pharmacy quote that does not match last year’s plan, or the annual ritual of re-proving type 1 diabetes to an insurer that already has the diagnosis on file. The clinical need is often not the confusing part. The paperwork is.

This post is a navigation map for prior authorization (PA), denial letters, and common appeal ladders. It is education about logistics many communities discuss. It is not legal advice, not a guarantee of coverage, and not a script that will win every appeal. Plans, states, Medicare Advantage, Medicaid, and employer policies differ. Your clinic, insurer member services, and (when needed) a patient advocate or attorney who knows your plan type still own the specifics.

Prior auth, in plain language

Prior authorization is a utilization-management step. Before the plan pays for certain drugs, devices, or durable medical equipment (DME), it asks for clinical documentation that the request meets its written criteria. For people with type 1 diabetes, that often lands on CGMs, insulin pumps and related supplies, preferred insulin products, and sometimes quantity or channel limits.

Why CGM and pump supplies hit PA so often:

• High cost and device categories. Plans treat sensors, transmitters, pumps, and infusion sets as specialty or DME items with criteria checklists.
• Formulary and preferred brands. A denial may be about product preference, not about whether you have diabetes.
• Visit and documentation timing. Some criteria ask for recent clinic notes, A1C or CGM summary language, or evidence of prior therapy. Missing one checkbox can look like a medical denial when it is really a paperwork gap.
• Annual re-proof culture. Forum themes often describe being asked to re-establish medical necessity even when the diagnosis has not changed. That is a plan-process complaint, not a clinical mystery.

Decoding a denial letter (what to hunt for)

When a denial arrives, treat it like a logistics document, not a personal verdict. Photocopy or screenshot the whole letter. Look for:

1. Reason codes or criteria cited. Is this “not medically necessary,” “experimental,” “wrong channel,” “quantity limit,” “step therapy,” or “missing information”? Different reasons point to different next packets.
2. Appeal deadlines. Internal appeal windows are often short. Mark the due date on a calendar the same day the letter lands.
3. What they say they still need. Chart notes, letter of medical necessity (LMN), pharmacy claim history, device download summary, or a different ICD or product code.
4. Who submitted the request. Clinic, pharmacy, DME supplier, or manufacturer hub. The denial trail may be sitting with a supplier you have never spoken to.
5. Plan level and member ID. Confirm the correct plan year and that the denial matches the ID on your card.

Community threads often skip this decode step and jump straight to “call the endo.” Calling the clinic helps. Knowing which checkbox failed helps more.

A common appeal sequence (education, not law)

Exact rights depend on plan type and state. Many commercial plans follow a rough ladder that looks like this:

1. Clinic and letter of medical necessity. Ask the diabetes care team (and sometimes the supplier) for an LMN that maps your devices and history to the criteria the denial cited. Include relevant chart notes, diagnosis documentation, and any prior therapy language the plan asked for. This is logistics support from your clinicians, not a promise of approval.
2. Insurer internal appeal. File within the deadline on the letter. Attach the LMN, notes, and a short cover page that restates the denial reason and the documents that answer it. Keep confirmation numbers.
3. External or state review. If the plan still denies after internal levels, many states and some federal rules allow independent external review for medical necessity disputes. Member services, your state insurance department website, or a patient-advocacy org can point to the form that matches your plan. This site does not draft legal filings for you.

Urgency and “expedited” paths sometimes exist when delay risks serious harm. Whether that label applies to your case is a plan and clinical judgment call, not something a blog can declare.

Pharmacy channel vs DME channel friction

Forum intensity spikes when the same CGM or pump supply is cheaper or smoother in one channel than another, or when a plan flips the channel mid-year. Educational framing:

• Pharmacy benefit often means retail or specialty pharmacy fill with a copay or coinsurance on the drug/device formulary side.
• DME / medical benefit often means a supplier bills the medical side, sometimes with different deductibles, prior-auth forms, and shipping delays.
• Mismatch pain. A denial can mean “wrong channel,” not “you do not need a CGM.” Ask which benefit owns the SKU before restarting the same PA in the wrong place.

Manufacturer patient-support hubs, preferred pharmacies, and DME suppliers sometimes run parallel paperwork. Knowing who owns the open ticket reduces duplicate calls.

Documenting medical necessity without inventing legal advice

What usually helps a clinic packet, in logistics language:

• Clear diagnosis documentation (type 1 diabetes) and how long you have used the device class, if relevant to criteria
• Recent visit notes that match the plan’s look-back window
• A short LMN that answers the specific denial reason, not a generic “patient needs CGM” paragraph alone
• Device or therapy history the criteria mention (for example, why a preferred alternative was tried, failed, or was not appropriate, if that is what the plan asked)
• Copies of prior approvals if the plan is re-asking for the same category

What this site will not do: invent case law, tell you which ICD codes to use, or claim a particular appeal letter wins. If the stakes are high or deadlines are confusing, ask your clinic’s prior-auth staff, a hospital financial counselor, or a qualified advocate for plan-specific help.

Light policy hook: INSULIN Act of 2026 (proposed)

Access friction is not only about devices. Insulin cost and commercial coverage rules keep showing up in the same community conversations. As of mid-2026 research and Congress.gov records, the bipartisan INSULIN Act of 2026 (S.4189) is proposed legislation aimed at reducing insulin costs and related patient protections for people with commercial coverage. Senate HELP committee action advanced the bill onto the Senate calendar; it is not enacted law as of this writing. A House companion has also been discussed in advocacy coverage.

Read the sourced news note on this site: INSULIN Act. Primary records: Congress.gov S.4189 and sponsor/coalition materials such as the Collins Senate release describing the proposed $35 monthly commercial insulin cap framing. Legislation status changes. Verify current status before treating any cap as settled policy.

Community themes, named as themes

Recurring public-forum motifs (not personal stories invented for this site): CGM denials despite established type 1 diabetes; pharmacy vs DME sticker shock; annual re-authorization fatigue; and wins that arrived only after an external review or a carefully matched LMN. Use those themes as motivation to organize paperwork early. Do not treat any single Reddit outcome as a template for your plan.

What this post is not

• Not legal advice, insurance counseling, or a promise that any appeal will succeed
• Not a claim that every denial is wrongful, or that every preferred-product rule is optional
• Not dosing advice, device prescribing, or a recommendation to start or stop any therapy
• Not a substitute for your clinic’s prior-auth team, member services, or state insurance resources
• Not a statement that the INSULIN Act is enacted law